A Phase 2, Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Voreloxin (Vosaroxin) Injection in Patients Equal to or Greater Than 60 Years of Age With Previously Untreated Acute Myeloid Leukemia

Trial Profile

A Phase 2, Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Voreloxin (Vosaroxin) Injection in Patients Equal to or Greater Than 60 Years of Age With Previously Untreated Acute Myeloid Leukemia

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Vosaroxin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms REVEAL-1
  • Sponsors Sunesis Pharmaceuticals
  • Most Recent Events

    • 24 Nov 2014 Results published in a Sunesis Pharmaceuticals media release and also published online in the British Journal of Haematology.
    • 26 May 2010 Status changed from active, no longer recruiting to completed.
    • 24 May 2010 Status cahnge from active, no longer recruiting to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top